

GEORGIA MEDICAID FEE-FOR-SERVICE ANTIDEPRESSANTS PA SUMMARY

Preferred	Non-Preferred
Preferred SSRIs Citalopram tablets, oral solution generic Escitalopram tablets generic	Non-Preferred SSRIs n/a
Fluoxetine IR capsules, oral solution generic Fluvoxamine IR generic Paroxetine IR tablets generic Sortroline generic	
Sertraline generic	N. D. G. LGYDY
Preferred SNRIs Desvenlafaxine succinate ER generic (generic Pristiq)	Non-Preferred SNRIs Fetzima (levomilnacipran)
Duloxetine capsules generic except 40 mg	Savella (milnacipran)
Venlafaxine IR tablets, ER capsules generic	Savena (minacipian)
Preferred Modified Cyclics	Non-Preferred Modified Cyclics
Trazodone 50, 100, 150 mg generic	Nefazodone generic
Trintellix (vortioxetine)*	Viibryd (vilazodone)
Preferred MAO Inhibitors	Non-Preferred MAO Inhibitors
n/a	Emsam (selegiline)
	Marplan (isocarboxazid)
	Phenelzine generic
	Tranylcypromine generic
Preferred TCAs	Non-Preferred TCAs
Amitriptyline generic	Protriptyline generic
Amoxapine generic	Trimipramine generic
Clomipramine generic by Mallinckrodt	
Desipramine generic Doxepin generic	
Imipramine hydrochloride tablets generic	
Nortriptyline generic	
Preferred Alpha-2 Receptor Antagonists	
Mirtazapine generic Mirtazapine ODT generic	
with azapine OD1 generic	
Preferred Miscellaneous Antidepressants	Non-Preferred Miscellaneous Antidepressants
Bupropion IR generic	Auvelity (dextromethorphan/bupropion)
Bupropion ER/SR generic	Spravato (esketamine)
Bupropion XL generic	Zurzuvae (zuranolone)

^non-preferred but does not require PA; SSRI=selective serotonin reuptake inhibitor; SNRI=serotonin norepinephrine reuptake inhibitor; MAO=monoamine oxidase; TCA=tricyclic antidepressant; IR=immediate-release; DR=delayed-release; ER/SR/XL=extended-release; PMDD=premenstrual dysphoric disorder

LENGTH OF AUTHORIZATION: Varies



NOTE: All starter/titration kits are only approvable for one time only for new starts (members being titrated on therapy).

PA CRITERIA:

Trintellix

❖ Approvable for members 18 years of age and older with major depressive disorder (MDD) who have experienced an inadequate response with at least 1 preferred generic antidepressant.

Fetzima

❖ Approvable for members 18 years of age or older with a diagnosis of major depressive disorder (MDD) who have experienced an inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects with the preferred products, venlafaxine (IR or ER) or desvenlafaxine ER or duloxetine.

Savella

❖ Approvable for members 18 years of age or older with a diagnosis of fibromyalgia who have experienced ineffectiveness, allergies, contraindications, drug-to-drug interactions or intolerable side effects to Lyrica or duloxetine.

Nefazodone Generic

❖ Approvable for members 18 years of age or older who have experienced an inadequate response with at least one preferred medication from any of the following groups: 1. SSRI (e.g., citalopram, escitalopram, fluoxetine, sertraline, paroxetine) 2. SNRI (e.g., venlafaxine, desvenlafaxine, duloxetine) 3. Other Antidepressants (e.g., bupropion, mirtazapine, trazodone, Trintellix).

Viibryd

❖ Approvable for members 18 years of age or older with a diagnosis of major depressive disorder (MDD) who have experienced an inadequate response with at least one preferred medication from any of the following groups: 1. SSRI (e.g., citalopram, escitalopram, fluoxetine, sertraline, paroxetine) 2. SNRI (e.g., venlafaxine, desvenlafaxine, duloxetine) 3. Other Antidepressants (e.g., bupropion, mirtazapine, trazodone, Trintellix)

Emsam

❖ Approvable for members 12 years of age or older with a diagnosis of major depressive disorder who have experienced an inadequate response with at least one preferred medication from any of the following groups: 1. SSRI (e.g., citalopram, escitalopram, fluoxetine, sertraline, paroxetine) 2. SNRI (e.g., venlafaxine, desvenlafaxine, duloxetine) 3. Other Antidepressants (e.g., bupropion, mirtazapine, trazodone, Trintellix).



• Otherwise, the member must be unable to take medications orally.

Marplan and Phenelzine Generic

Approvable for members 16 years of age or older with a diagnosis of major depressive disorder who have experienced an inadequate response with at least one preferred medication from any of the following groups: 1. SSRI (e.g., citalopram, escitalopram, fluoxetine, sertraline, paroxetine) 2. SNRI (e.g., venlafaxine, desvenlafaxine, duloxetine) 3. Other Antidepressants (e.g., bupropion, mirtazapine, trazodone, Trintellix).

Tranylcypromine Generic

- ❖ Approvable for members 16 years of age or older with a diagnosis of major depressive disorder who have experienced an inadequate response with at least one preferred medication from any of the following groups: 1. SSRI (e.g., citalopram, escitalopram, fluoxetine, sertraline, paroxetine) 2. SNRI (e.g., venlafaxine, desvenlafaxine, duloxetine) 3. Other Antidepressants (e.g., bupropion, mirtazapine, trazodone, Trintellix).
- ❖ Approvable for members 16 years of age or older with a diagnosis of neurogenic orthostatic hypotension.

Protriptyline Generic

- ❖ Approvable for members with a diagnosis of major depressive disorder who have experienced an inadequate response, allergies, contraindications, drugdrug interactions or intolerable side effects with at least 1 preferred tricyclic antidepressant.
- ❖ Approvable for members with a diagnosis of chronic obstructive pulmonary disease (COPD) or sleep apnea.

Trimipramine Generic

❖ Approvable for members with a diagnosis of major depressive disorder who have experienced an inadequate response, allergies, contraindications, drugdrug interactions or intolerable side effects with at least 1 preferred tricyclic antidepressant.

Auvelity

❖ Approvable for members 18 years of age or older with a diagnosis of major depressive disorder who have experienced an inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects with at least 1 preferred generic antidepressant.

Spravato

❖ Approvable for members 18 years of age or older with a diagnosis of treatment-resistant major depressive disorder who have a baseline scoring in at least one clinical assessment prior to initiation to evaluate efficacy (e.g., HAMD17, QIDS-C16, MADRS, PHQ-9) and when prescribed by or in consultation with a psychiatrist, when administered under the direct



supervision of a healthcare provider and monitored by a healthcare provider for at least 2 hours after and when administered in conjunction with a newly initiated daily oral antidepressant

AND

❖ Member must have experienced an inadequate response with at least 1 preferred generic antidepressant

OR

❖ Approvable for members 18 years of age or older with a diagnosis of depressive symptoms with major depressive disorder (MDD) with acute suicidal ideation or behavior and when prescribed by or in consultation with a psychiatrist, when administered under the direct supervision of a healthcare provider and monitored by a healthcare provider for at least 2 hours after and when administered in conjunction with a newly initiated daily oral antidepressant.

Zurzuvae

❖ Approvable for members 18 years of age or older with a diagnosis of severe postpartum depression (PPD) who have been postpartum for 12 months or less and have a baseline scoring in at least one clinical assessment (e.g., HAMD-17, PHQ-9) that is consistent with severe depression with symptoms beginning during the third trimester of pregnancy or up to 4 weeks post-delivery

AND

❖ When prescribed by or in consultation with a psychiatrist or obstetrician/gynecologist (OB/GYN).

EXCEPTIONS:

- Exceptions to these conditions of coverage are considered through the prior authorization process.
- ❖ The Prior Authorization process may be initiated by calling OptumRx at 1-866-525-5827.

PREFERRED DRUG LIST:

❖ For online access to the Preferred Drug List (PDL), please go to http://dch.georgia.gov/preferred-drug-lists.

PA and APPEAL PROCESS:

❖ For online access to the PA process, please go to www.dch.georgia.gov/prior-authorization-process-and-criteria and click on Prior Authorization (PA) Request Process Guide.

QUANTITY LEVEL LIMITATIONS:

❖ For online access to the current Quantity Level Limits (QLL), please go to www.mmis.georgia.gov/portal, highlight Provider Information and click on Provider Manuals. Scroll to the page with Pharmacy Services and select that manual.